Rituximab in the treatment of severe lupus myelopathy

Clinical Rheumatology

Volumn 30, Issue 7, 2011, Pages 981-986

  Ye, Yan ^a   Qian, Jie ^a   Gu, Yueying ^a   Chen, Xiaoqing ^b   Ye, Shuang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Myelitis; Myelopathy; Rituximab; Systemic lupus erythematosus

Indexed keywords

CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; METHYLPREDNISOLONE; PREDNISONE; RITUXIMAB;

ABSCESS; ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; DECUBITUS; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEMUR HEAD NECROSIS; HUMAN; LUPUS MYELOPATHY; MALE; MUSCLE STRENGTH; PRIORITY JOURNAL; RELAPSE; RESPIRATORY TRACT INFECTION; SOFT TISSUE ABSCESS; SPINAL CORD DISEASE; TREATMENT RESPONSE; URINARY TRACT INFECTION;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; DRUG THERAPY, COMBINATION; FEMALE; HEALTH STATUS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MUSCLE STRENGTH; MYELITIS; PREDNISONE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; URINARY TRACT INFECTIONS; YOUNG ADULT;

EID: 79959599976     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-011-1714-5     Document Type: Article

References (19)

1. Kovacs B, Lafferty TL, Brent LH, DeHoratius RJ (2000) Transverse mylopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literature. Ann Rheum Dis 59:120-124 (Pubitemid 30305609)
2. Frohman EM, Wingerchuk DM (2010) Transverse myelitis. N Engl J Med 363:564-572
3. Lu X, Gu Y, Wang Y, Chen S, Ye S (2008) Prognostic factors of lupus myelopathy. Lupus 358:676-688
4. Mok CC, Lau CS, Chan EY, Wong RW (1998) Acute transverse myelopathy in systemic lupus erythematosus: clinical presentation, treatment, and outcome. J Rheumatol 25:467-473 (Pubitemid 28109347)
5. Katsiari CG, Giavri I, Mitsikostas DD, Yiannopoulou KG, Sfikakis PP (2010) Acute transverse myelitis and antiphospholipid antibodies in lupus. No evidence for anticoagulation. Eur J Neurol. doi:10.1111/j.1468-1331
6. Birnbaum J, Petri M, Thompson R, Izbudak I, Kerr D (2009) Distinct subtypes of myelitis in systemic lupus erythematosus. Arthritis Rheum 60:3378-3387
7. de Seze J, Lanctin C, Lebrun C et al (2005) Idiopathic acute transverse myelitis: application of the recent diagnostic criteria. Neurology 65:1950-1953 (Pubitemid 43970116)
8. Heinlein AC, Gertner E (2007) Marked inflammation in catastrophic longitudinal myelitis associated with systemic lupus erythematosus. Lupus 16:823-826 (Pubitemid 350069796)
9. Espinosa G, Mendizabal A, Minguez S et al (2010) Transverse myelitis affecting more than 4 spinal segments associated with systemic lupus erythematosus: clinical, immunological, and radiological characteristics of 22 patients. Semin Arthritis Rheum 39:246-256
10. Hauser SL, Waubant E, Arnold DL et al (2008) B-cell depletion with Rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358:676-678
11. Tokunaga M, Saito K, Kawabata D et al (2007) Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 66:470-475 (Pubitemid 46580466)
12. Armstrong DJ, McCarron MT, Wright GD (2006) SLE-associated with transverse myelitis successfully treated with Rituximab (anti-CD20 monoclonal antibody). Rheumatol Int 26:771-772 (Pubitemid 43725476)
13. Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725
14. Yee CS, Farewell V, Isenberg DA et al (2006) Revised British Isles lupus assessment group 2004 index: a reliable tool for assessment of systemic lupus erythematosus activity. Arthritis Rheum 54:3300-3305 (Pubitemid 44622101)
15. Steeves JD, Lammertse D, Curt A et al (2007) Guidelines for the conduct of clinical trials for spinal cord injury (SCI) as developed by the ICCP panel: clinical trial outcome measures. Spinal Cord 45:206-221 (Pubitemid 46340849)
16. Morganti B, Scivoletto G, Ditunno P, Ditunno JF (2005) Walking index for spinal cord injury (WISCI): criterion validation. Spinal Cord 43:27-33 (Pubitemid 40116466)
17. Ramos-Casals M, Soto MJ, Cuadrado MJ, Khamashta MA (2009) Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus 18:767-776
18. Terrier B, Amoura Z, Ravaud P et al (2010) Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French autoimmunity and rituximab registry. Arthritis Rheum 62:2458-2466
19. Merrill JT, Neuwelt CM, Wallace DJ et al (2010) Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 62:222-233